Business Description
Phathom Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US71722W1071
Share Class Description:
PHAT: Ordinary sharesTotal Employee Number:
371Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.09 | |||||
Equity-to-Asset | -1.05 | |||||
Debt-to-Equity | -0.49 | |||||
Debt-to-EBITDA | -4.76 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -5.07 | |||||
Beneish M-Score | -2.26 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 21.6 | |||||
3-Year EPS without NRI Growth Rate | 25.8 | |||||
3-Year FCF Growth Rate | 15.3 | |||||
3-Year Book Growth Rate | -50.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 57.71 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.75 | |||||
9-Day RSI | 23.62 | |||||
14-Day RSI | 29.78 | |||||
3-1 Month Momentum % | -11.08 | |||||
6-1 Month Momentum % | -9.75 | |||||
12-1 Month Momentum % | 33.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 1.87 | |||||
Cash Ratio | 1.19 | |||||
Days Inventory | 47.76 | |||||
Days Sales Outstanding | 110.66 | |||||
Days Payable | 38.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.9 | |||||
Shareholder Yield % | -17.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.92 | |||||
Operating Margin % | -16.96 | |||||
Net Margin % | -41.34 | |||||
EBITDA Margin % | -14.66 | |||||
FCF Margin % | -15.4 | |||||
OCF Margin % | -15.31 | |||||
ROA % | -35.85 | |||||
ROIC % | -53.71 | |||||
3-Year ROIIC % | 18.6 | |||||
ROC (Joel Greenblatt) % | -1077.73 | |||||
ROCE % | -22.67 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.71 | |||||
EV-to-EBIT | -18.61 | |||||
EV-to-EBITDA | -18.88 | |||||
EV-to-Revenue | 2.77 | |||||
EV-to-Forward-Revenue | 2.07 | |||||
EV-to-FCF | -17.97 | |||||
Earnings Yield (Greenblatt) % | -5.37 | |||||
FCF Yield % | -5.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PHAT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Phathom Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 239.663 | ||
| EPS (TTM) ($) | -1.28 | ||
| Beta | 1.637 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.4 | ||
| Volatility % | 62.27 | ||
| 14-Day RSI | 29.78 | ||
| 14-Day ATR ($) | 0.781695 | ||
| 20-Day SMA ($) | 10.7505 | ||
| 12-1 Month Momentum % | 33.65 | ||
| 52-Week Range ($) | 8.025 - 18.31 | ||
| Shares Outstanding (Mil) | 80.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Phathom Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Phathom Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 08:00 | In 86 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 85 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 08:00 | 11.64 (-2.35%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 11.64 (-2.35%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 14:40 | 10.00 (-1.77%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 12:15 | 9.65 (+6.39%) | ||
| General meeting for 2026 | 2026-05-19 09:00 | 11.39 (-5.08%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 08:00 | 11.78 (+4.43%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 11.78 (+4.43%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-15 13:30 | 12.67 (-0.39%) |
Show
Entries
Phathom Pharmaceuticals Inc Frequently Asked Questions
What is Phathom Pharmaceuticals Inc(PHAT)'s stock price today?
The current price of PHAT is $8.39. The 52 week high of PHAT is $18.31 and 52 week low is $8.03.
When is next earnings date of Phathom Pharmaceuticals Inc(PHAT)?
The next earnings date of Phathom Pharmaceuticals Inc(PHAT) is .
Does Phathom Pharmaceuticals Inc(PHAT) pay dividends? If so, how much?
Phathom Pharmaceuticals Inc(PHAT) does not pay dividend.
Guru Commentaries on NAS:PHAT
No articles.
Press Release
Articles on Phathom Pharmaceuticals Inc
Headlines
See More- 1
Jul 31, 2026
Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4
Seeking Alpha • 7:44pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers